OKYO Pharma Ltd. (OKYO), on Monday, said it has appointed Robert Dempsey as Chief Executive Officer, effective immediately.
Robert Dempsey will take over from Gary Jacob, who has transitioned to the role of chief development officer and will continue to serve as a board member.
The company said Dempsey brings more than two decades of global ophthalmology experience spanning drug development, commercialization and strategic transactions.
Dempsey previously served as group vice president and head of global ophthalmology at Shire.
The company said the leadership change is intended to support the next phase of growth, with a focus on advancing its lead asset, urcosimod, for the treatment of neuropathic corneal pain and other ocular inflammatory diseases.
On Friday, OKYO Pharma closed trading 7.21% higher at $2.2300 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.